Medigen Biotechnology (ROCO:3176) Short-Term Capital Lease Obligation : NT$18 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Short-Term Capital Lease Obligation?

Medigen Biotechnology's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$18 Mil.

Medigen Biotechnology's quarterly Short-Term Capital Lease Obligation declined from Sep. 2023 (NT$18 Mil) to Dec. 2023 (NT$17 Mil) but then increased from Dec. 2023 (NT$17 Mil) to Mar. 2024 (NT$18 Mil).

Medigen Biotechnology's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (NT$3 Mil) to Dec. 2022 (NT$13 Mil) and increased from Dec. 2022 (NT$13 Mil) to Dec. 2023 (NT$17 Mil).

Medigen Biotechnology Short-Term Capital Lease Obligation Historical Data

The historical data trend for Medigen Biotechnology's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Short-Term Capital Lease Obligation Chart

Medigen Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

11.46

3.02

3.32

13.13

17.32

Medigen Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															13.21	18.04	17.83	17.32	17.88

Medigen Biotechnology Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Medigen Biotechnology Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology (ROCO:3176) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560

Website

https://www.medigen.com.tw

Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines